The stock of Craneware plc (LON:CRW) is a huge mover today! The stock decreased 5.71% or GBX 57.5 on November 24, hitting GBX 950. About 22,614 shares traded hands or 2.78% up from the average. Craneware plc (LON:CRW) has risen 21.38% since April 28, 2016 and is uptrending. It has outperformed by 15.97% the S&P500.
The move comes after 5 months negative chart setup for the GBX 257.61 million company. It was reported on Nov, 24 by Barchart.com. We have GBX 874.00 PT which if reached, will make LON:CRW worth GBX 20.61 million less.
Craneware plc (LON:CRW) Ratings Coverage
Out of 3 analysts covering Craneware (LON:CRW), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Craneware has been the topic of 18 analyst reports since July 16, 2015 according to StockzIntelligence Inc. Peel Hunt maintained the stock with “Buy” rating in Thursday, November 10 report. The firm has “Buy” rating by Investec given on Tuesday, March 8. Peel Hunt maintained Craneware plc (LON:CRW) on Thursday, April 28 with “Buy” rating. On Thursday, September 15 the stock rating was maintained by Peel Hunt with “Buy”. Peel Hunt maintained Craneware plc (LON:CRW) rating on Tuesday, September 6. Peel Hunt has “Buy” rating and GBX 1335 price target. Peel Hunt maintained Craneware plc (LON:CRW) rating on Monday, January 11. Peel Hunt has “Buy” rating and GBX 920 price target. The stock has “Buy” rating given by Peel Hunt on Wednesday, July 6. As per Tuesday, September 8, the company rating was maintained by Investec. Peel Hunt maintained it with “Buy” rating and GBX 920 target price in Friday, November 20 report. Investec maintained it with “Buy” rating and GBX 915 target price in Friday, January 22 report.
Craneware plc is a United Kingdom-based company, which is engaged in the development, licensing and ongoing support of computer software for the United States healthcare industry. The company has a market cap of 257.61 million GBP. The Company’s Value Cycle Solutions span over five product families, which include Patient Engagement, Charge Capture & Pricing, Coding Integrity, Cost Analytics, and Revenue Collection & Retention. It has a 30.34 P/E ratio. The Company’s Patient Engagement solutions include InSight Medical Necessity, Trisus Patient Payment and Patient Charge Estimator.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.